Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)
|
|
- Roy Page
- 5 years ago
- Views:
Transcription
1 Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to 11/06/12. Note: Not all respondents answered all questions, so totals for individual questions vary. This survey was sent only to EIN members with an adult infectious diseases practice. Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) Mid Atlantic 93 (50% of 186 members) East North Central 95 (54% of 177 members) West North Central 61 (54% of 112 members) South Atlantic 108 (49% of 220 members) East South Central 28 (50% of 56 members) West South Central 33 (41% of 80 members) Mountain 40 (58% of 69 members) Pacific 105 (52% of 203 members) Puerto Rico 1 (20% of 5 members) Canada 7 (39% of 18 members) Years experience since ID fellowship: <5 years 129 (43% of 302 members) (44% of 350 members) (61% of 288 members) (59% of 273 members) Employment: Hospital/clinic 175 (52% of 334 members) Private/group practice 212 (53% of 399 members) University/medical school 183 (46% of 394 members) VA and military 45 (58% of 78 members) State gov t 6 (75% of 8 members) Primary hospital type: Community Non-university teaching University VA hospital or DOD City/county Other 181 (50% of 365 members) 190 (54% of 349 members) 173 (47% of 366 members) 46 (57% of 81 members) 21 (55% of 38 members) 10 (71% of 14 members) *Respondents were significantly more likely than non-respondents to have at least 15 years of ID experience (p<0.0001). Page 1
2 Question 1. Estimated number of patients with CDI treated in the last 6 months sorted by the number of those patients having at least one relapse of CDI. [602 respondents] Pts with CDI Pts with recurrent CDI Number (%) None None 64* (11%) 1-10 None 16 (3%) (24%) (3%) None 6 (1%) (12%) (19%) (3%) None (2%) (8%) (7%) >25 8 (1%) >50 None (0.8%) (3%) >25 11 (2%) *The 64 members who responded that they do not treat CDI are not included in further analyses Question 2. Treatment choices for the following CDI indications [column percentages shown]: [Instructions were to select all that apply; numbers add to more than 100%] Primary episode mild disease 1 st relapse mild disease 2 nd relapse mild disease Number of respondents Oral metronidazole 449* (84%) 215 (40%) 17 (3%) Oral vancomycin 87 (16%) 347 (65%) 282 (53%) Fidaxomicin 1 (0.2%) 20 (4%) 60 (11%) Oral vancomycin taper (15%) 290 (55%) Rifaximin chaser -- 9 (2%) 73 (14%) Nitazoxanide -- 1 (0.2%) 10 (2%) Tigecycline -- 1 (0.2%) 3 (0.6%) Any form of vancomycin 87 (16%) 364 (68%) 495 (94%) chosen (oral course or taper) Combination therapy ( 2) (24%) 121 (23%) *235 (52%) of the 449 respondents who initially chose oral metronidazole switched to another agent for the first relapse. 85 (98%) of the 87 respondents who initially chose oral vancomycin continued with vancomycin ± another agent; one respondent switched to oral metronidazole; one switched to fidaxomicin. Page 2
3 Duration of treatment for second relapse, mild disease: [285 respondents] days 122 (43%) days 82 (29%) days 68 (24%) >56 days 13 (4%) Question 3. For a third (or subsequent) relapse, would your treatment choices change from above? No 143 (27%) Yes 392 (73%) If yes, how? The following treatment choices were mentioned in this open text field: Vancomycin pulse and/or taper and/or longer course mentioned 190 times Fidaxomicin mentioned 119 times Rifaximin mentioned 72 times FMT mentioned 70 times IVIG mentioned 9 times Nitazoxanide mentioned 5 times Question 4a. Does your institution offer testing for the NAP1 (BI/027) strain? Not sure 39 (7%) No 365 (68%) Yes 134 (25%) Question 4b. Would your treatment choices change if your patient was known to carry the NAP1 strain? Not sure 153 (28%) No 225 (42%) Yes 160 (30%) Question 5. Treatment choices for the following CDI indications [column percentages shown]: [Instructions were to select all that apply; numbers add to more than 100%] [533 respondents] Severe disease without ileus Severe disease with ileus Oral metronidazole 30 (6%) 12 (2%) Oral vancomycin 514 (96%) 327 (61%) IV metronidazole 252 (47%) 481 (90%) Vancomycin per rectum 57 (11%) 365 (68%) Fidaxomicin 30 (6%) 31 (6%) Rifaximin 20 (4%) 13 (2%) Tigecycline 18 (3%) 53 (10%) ---Oral vancomycin alone selected by the single largest group of respondents (N=224, 42%) for severe disease without ileus ---The combination of oral vancomycin, intravenous metronidazole and vancomycin per rectum was chosen by the single largest group of respondents (N=160, 30%) for severe disease with ileus Page 3
4 Question 6. Have you ever used/recommended IVIG in the treatment of patients with CDI? No 264 (49%) Yes 274 (51%) If yes, how many times? <5 times 211 (77%) 5-10 times 42 (16%) >10 times 19 (7%) Question 7. Do you recommend probiotics (including Saccharomyces boulardii) for: management of current CDI? prevention of CDI (pt on antibiotics) No 243 (46%) 268 (50%) Yes, rarely 79 (15%) 80 (15%) Yes, occasionally 121 (23%) 120 (23%) Yes, routinely 91 (17%) 64 (12%) Question 8. Circumstances under which you would recommend Fecal Microbiota Transplantation (FMT): [Select all that apply; numbers add to more than 100%] [527 respondents] No circumstances/would not recommend 47 (9%) Recurrent disease 424 (80%) Severe disease 125 (24%) Other 54 (10%) If FMT recommended for recurrent disease, after how many relapses? [406 respondents] One 9 (2%) Two 94 (23%) Three 165 (41%) Four 53 (13%) Five 31 (8%) Six 5 (1%) Eight 2 (0.5%) Range typed in as from one to three 10 (2%) Range typed in as from four to eight 21 (5%) Typed in as depends or arbitrary 2 (0.5%) Typed in as multiple or several 14 (3%) Question 9. Is FMT currently available in your primary institution? No 249 (47%) Not yet but we are working on it 127 (24%) Yes 156 (29%) Page 4
5 Question 10. If FMT is not available in your institution, why not? [Instructions were to select all that apply; numbers add to more than 100%] [330 respondents] Patient refusal 15 (5%) Compensation/reimbursement issues 84 (26%) Complexity/costs of donor testing 147 (45%) Logistics of FMT preparation and delivery 265 (80%) Other* 41 (12%) *In open text field, other barriers mentioned included: Haven t needed it /No requests for it by 19, IRB approval/legal issues by 16, Conflicts/issues with Gastroenterology by 15, Available at nearby hospital by 11; Hospital administration barriers/resistance by 9. Question 11. Have you observed any transmissible diseases or other complications that have been associated with FMT? [488 respondents] Not sure 83 (17%) No 402 (82%) Yes* 3 (0.6%) *Recurrence of CDI after transplant (N=2); HIV/hepatitis B & C (N=1) Fecal Microbiota Transplantation (FMT) Subsurvey N=149 respondents Question 1. How many patients under your care have receive FMT in the past year? None, but others in my institution/group provide FMT 42 (28%) (53%) (15%) (3%) >25 2 (1%) Question 2. What labs do you recommend for the FMT donors? [Instructions were to select all that apply; numbers add to more than 100%] [144 respondents] None 6 (4%) HIV 126 (88%) Hepatitis B 123 (85%) Hepatitis C 113 (78%) Hepatitis A 107 (74%) Stool for C. difficile 105 (73%) Stool culture 100 (69%) Stool for O&P 94 (65%) RPR 80 (56%) CMV 19 (13%) Other 11 (8%) Page 5
6 Question 3. How is FMT usually administered? NG tube / nasojejunal tube 47 (33%) Enema 27 (19%) Colonoscopy 69 (48%) Question 4. What is the usual source of the donated material? Family/household member 141 (98%) Donor pool (fresh) 0 Frozen, banked material 3 (2%) Question 5. How many instillations are usual for each patient receiving FMT? Single instillation 125 (91%) Multiple instillations 12 (9%) Question 6. What is your usual volume range per instillation? <100 ml 23 (20%) ml 53 (47%) ml 30 (27%) ml 7 (6%) >1000 ml 0 Question 7. What is your estimated success rate with FMT? <50% 2 (2%) 50-79% 19 (15%) 80-95% 48 (38%) >95% 56 (45%) Page 6
21 (49% of 43 members) Both adult and pediatric 22 (34% of 65 members) Region: New England 54 (55% of 98 members) 288 (52% of 549 members)
9 December 01 Infectious Diseases Society of America Emerging Infections Network Report for Query: Use of Respiratory Protective Devices for Influenza Overall response rate: 686/1,7 (7%) physicians responded
More informationResponders as percent of overall members in each category: Region: New England 50 (58% of 86 members) 19 (51% of 37 members) 3 (33% of 9 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Prosthetic Joint Infections (PJI) in Adults Overall response rate: 556/118 (4.2%) physicians responded from 5/16/12
More informationResponders as percent of overall members in each category: Practice: Adult 537 (51% of 1063 members) 23 (59% of 39 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Antibiotic Allergies and Infectious Disease Practice Overall response rate: 744/1411 (52.7%) physicians responded from
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationBoth adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.
More informationFecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,
More informationClostridium difficile (C difficile)
Patient Knowledge and Attitudes About for Clostridium difficile Infection Colin Goodman, MD; Nicholas O Rourke, PharmD; Carla Amundson, MA; and Dimitri Drekonja, MD, MS In a survey of patients with Clostridium
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More informationIs FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016
Is FMT the answer? Challenging Cases in CDI Ted Steiner, M.D. April 1, 2016 CONFLICT OF INTEREST DISCLOSURE SLIDE In the past 2 years I have been an employee of: In the past 2 years I have been a consultant
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOverall response rate: 701/1265 (55.4%) physicians responded from 3/4/09 to 3/30/09.
Infectious Diseases Society of America Emerging Infections Network 4/2/09 Report for Query: Travel and Tropical Medicine Overall response rate: 701/1265 (55.4%) physicians responded from 3/4/09 to 3/30/09.
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationC. difficile: When to Do Fecal Microbiota Transplant (FMT)
C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationOngoing Developments in Management of Clostridium difficile Infection
Ongoing Developments in Management of Clostridium difficile Infection Infectious Diseases Spring Symposium Creighton University School of Medicine April 28, 2018, Omaha, NB Stuart Johnson, MD Loyola U.
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationClinical Infectious Diseases Advance Access published December 7, 2012
Clinical Infectious Diseases Advance Access published December 7, 2012 1 Physician Attitudes Towards the Use of Fecal Transplantation for Recurrent Clostridium Difficile Infection in a Large Metropolitan
More informationStar Articles in Review
Star Articles in Review CDDW/CASL Meeting Toronto, February 10, 2014 Christina M. Surawicz, MD MACG Professor of Medicine Division of Gastroenterology Department of Medicine University of Washington Disclosure
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationWhen To Do Fecal Microbiota Transplant (FMT) For C. difficile
When To Do Fecal Microbiota Transplant (FMT) For C. difficile Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationClinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome)
Clinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome) Criteria Codes Revision History Kaiser Foundation Health Plan
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationTitle: Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease
Title: Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease Authors: Marta Gravito-Soares, Elisa Gravito-Soares, Francisco
More informationGut Microbiota Transplant Pro Position. Christina Surawicz, MD, MACG Professor of Medicine University of Washington Seattle WA
Gut Microbiota Transplant Pro Position Christina Surawicz, MD, MACG Professor of Medicine University of Washington Seattle WA My Focus Recurrent Clostridium difficile infection No uniformly successful
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More informationTreating and Preventing. C. difficile Infections A Review of the Research for Adults
Treating and Preventing C. difficile Infections A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional has said that
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-DE Medical Management Provider Notice Date: 10/15/2018; 04/15/2018 Issue Date: 11/15/2018;
More informationFecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection
Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Juul FE, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation
More informationPatient Safety Summit 2014
Patient Safety Summit 2014 The War on C Diff Mark Mellow, MD + C Diff The Organism Gram + bacillus Anaerobic Spore forming Intestinal flora (up to 35% hospitalized patients, 3% of healthy adults) Leading
More informationVirtual Lectures Planning Committee Disclosure Summary
Mayo Medical Laboratories Virtual Lectures 2014 MFMER Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationUpdate on C. difficile: Diagnosis and Therapy Including Fecal Transplant
Update on C. difficile: Diagnosis and Therapy Including Fecal Transplant Colleen R. Kelly, MD Clinical Assistant Professor of Medicine Brown University Warren Alpert School of Medicine Rhode Island Chapter,
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationUpdates in Fecal Microbial Transplant
Updates in Fecal Microbial Transplant Dina Kao, MD FRCPC Associate Professor, Gastroenterology University of Alberta Nikhil Pai, MD FAAP FRCPC Assistant Professor, Ped Gastroenterology McMaster University
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationFecal transplantation as a treatment option for recurrent Clostridium difficile infection
Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationDisclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies
Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in
More informationClostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018
Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention
More informationInitial Experience of Faecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection in Hong Kong
HA Convention 2018 Initial Experience of Faecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection in Hong Kong Rashid NS Lui MBChB (CUHK), MRCP (UK), FHKCP Division of Gastroenterology
More informationACP Aaron Fieker, D.O
ACP 2016 Aaron Fieker, D.O Colorectal cancer (CRC) Update on screening strategies and tools Irritable Bowel Syndrome (IBS) New therapeutic options C-difficile Updates on treating recurrent disease CRC
More informationdeclara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.
Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,
More information(No Image Selected) Video Submission Confirmation: No Video Upload: Abstract Author: Investigator Commercial Products or Services: No Designed Study:
Found 3 Abstracts CONTROL ID: 1745628 TITLE: Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients CONTACT (NAME ONLY): Colleen Kelly
More informationA Physician Perspective. Marguerite A. Neill, MD Alpert Medical School Brown University Culture Independent Diagnostics Forum April 24, 2012
A Physician Perspective Marguerite A. Neill, MD Alpert Medical School Brown University Culture Independent Diagnostics Forum April 24, 2012 For diagnostics, It s all about context. The Clinical Drivers
More informationFecal microbiota transplantation (FMT) for Clostridium difficile colitis
Fecal microbiota transplantation (FMT) for Clostridium difficile colitis Patrick Knight 1, John P. Anagnostakos 1, Maggie J. Lin 1, Berhanu Geme 1, Stanislaw P. A. Stawicki 1,2 1 St. Luke s University
More informationThe good, the bad and the ugly. Our microbiome and it s effect on health and disease.
The good, the bad and the ugly Our microbiome and it s effect on health and disease. Objectives Discuss C difficile infection including treatment options Explain process of Fecal MicrobiotaTransplantation
More informationClinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection
Clinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection Zain Kassam MD, MPH, FRCPC Chief Medical Officer, OpenBiome Disclaimer
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-PA Medical Management Provider Notice Date: 10/15/2018; 01/15/2018 Issue Date: 11/15/2018;
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationObjectives RECENT ADVANCES IN FECAL MICROBIOTA TRANSFORMATION. TRANSPLANT in Inflammatory Bowel Disease
RECENT ADVANCES IN FECAL MICROBIOTA TRANSFORMATION TRANSPLANT in Inflammatory Bowel Disease David Suskind M.D. Professor of Pediatrics Division of Gastroenterology University of Washington Seattle Children
More informationPerspectives on the PUNCH CD Trial of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection
Perspectives on the PUNCH CD Trial of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection Kathy Tracey, LPN, CCRC, Chevy Chase Clinical Research, Chevy Chase, MD Mary Kay Sobcinski,
More informationFecal microbial transplantation
Version 09/16 Consent Form For Fecal microbial transplantation Fecal transplant is an operation in which liquid produced from a healthy human being (as per a survey questionnaire and blood and feces tests)
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationFECAL TRANSPLANTATION
FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome
More informationClostridium difficile: what are the best preventive and therapeutic options. Domitília Faria. Unidade Portimão/Lagos Centro Hospitalar do Algarve
Clostridium difficile: what are the best preventive and therapeutic options Domitília Faria Unidade Portimão/Lagos Centro Hospitalar do Algarve 19th INFECTION AND SEPSIS SYMPOSIUM, Porto 26/28 Fevereiro
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationFecal Microbiota Transplantation. Description
Section: Medicine Effective Date: April 15, 2017 Original Policy Date: September 12, 2014 Subject: Fecal Microbiota Transplantation Page: 1 of 10 Last Review Status/Date: March 2017 Fecal Microbiota Transplantation
More informationBacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management
Bacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management Dale N. Gerding, MD, MACP Professor of Medicine Loyola University
More informationClostridium difficile infections Crappy Options
Clostridium difficile infections Crappy Options Alexandru Petre David MD Infectious Diseases April 21, 2015 Objectives Microbiology Epidemiology Who is at risk? Pathogenesis Diagnosis Treatment Historical
More informationNursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationTreatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department
Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of
More informationClostridium difficile coli%s. John K. Midturi January 2013
Clostridium difficile coli%s John K. Midturi January 2013 Objec%ves Describe pathogenesis of C. Diff coli%s Review methods of diagnosis of C. Diff coli%s Discuss treatment op%ons first episode refractory
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationNote: Active Table of Contents Click to follow link
Clostridium difficile Infection: Prevention, Diagnosis and Treatment Adult/Pediatric Inpatient/Ambulatory/Emergency Department Clinical Practice Guideline Note: Active Table of Contents Click to follow
More informationClostridium difficile
Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus www.seacourses.com 1 Learning Points
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More information